Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer

Table 1 Patient characteristics and response

Pt #	Gender	Histology	Metastatic disease site	Vax #	Clinical response before immunotherapy	Clinical response after immunotherapy	Additional treatment before immunotherapy	Adverse effects (grade)	Survival in months
01	F	CC	Liver	1	PD	PD	Sunitinib	No	20 m+
02	M	CC	Lung, bone	1	PD	PD	None	No	20 m+
03	M	CC	Lung, bone	1	PD	PR	None	No	20 m+
04	M	CC	Lung, bone	2	PD	SD	None	No	19 m+
05	M	CC	Lung, Liver	6	SD	PR	None	No	19 m+
06	M	CC	Bone	4	PD	SD	None	No	18 m+
07	M	CC	Bone	1	PD	SD	None	No	17 m+
08	M	CC	Lung	4	SD	PR	None	No	18 m+
09	M	CC	Lung, Liver, Brain	2	PD	SD	None	No	21 m+
10	M	CC	Chest	3	PD	SD	None	No	16 m+
11	M	CC	Lung	1	PD	PR	None	No	16 m+
12	M	CC	Liver	1	PD	PD	None	Fever (grade1)	15 m+
13	M	CC	Neck lymph	1	PD	CR	None	No	10 m+
14	M	CC	Lung	1	PD	SD	None	No	10 m+
15	M	CC	Lung	3	PD	PR	None	No	9 m+
16	M	CC	Lung	3	PD	CR	None	No	10 m+
17	M	CC	Abdominal	1	PD	CR	None	No	15 m+
18	M	CC	Lung	1	PD	PD	None	No	12 m+
19	M	CC	peritoneum lymph	1	SD	PR	None	No	21 m+
20	F	CC	Liver, Bone	1	PD	PD	None	No	15 m+
21	F	CC	Abdominal	2	PD	PD	None	No	16 m+
22	M	CC	Bone	2	SD	CR	sorafenib	No	20 m+
23	M	CC	Lung, Bone	3	SD	SD	None	No	6 m+
24	F	CC	Lung, Bone	1	PD	death	None	No	4 m+
25	M	CC	Lung, Liver	3	PD	PR	Sorafenib + Sunitinib	No	6 m+
26	F	CC	Peritoneum lymph	2	SD	SD	None	No	11 m+
27	M	CC	Lung, Bone	2	PD	SD	None	No	5 m+
28	M	CC	Lung	2	SD	SD	sorafenib	No	5 m+

Abbreviations: PT patient, VAX vaccination, M male, CC renal clear cell carcinoma, F female, SD stable disease, CR completed response, PR partial response, PD progression of disease.

ISSN: 1471-2407